PDA The Future of Drug Delivery Workshop 2024
Registration Options
Individual Registration
Group Registration
Program Highlights
Join this one-day interactive workshop after the PDA Medical Devices an Connected Health Conference 2024 , and join the discussion discussion with industry experts on micro needle systems and wearable injection devices!
Dear Colleagues,
We would like to invite you to the PDA The Future of Drug Delivery Workshop 2024 taking place on 06 June 2024 in Antwerp, Belgium.
The workshop directly follows the PDA Medical Devices and Connected Health Conference 2024 and provides a useful context and perspective on the technologies, opportunities and realities of drug delivery – injectable and non-injectable – with a look at devices but also formulation technologies.
In a packed one-day program, acknowledged industry expert speakers will share their experience and insights on topics including the development, manufacture and regulatory aspects of drug delivery.
With GLP-1s being on everybody’s mind we will open the workshop with a presentation from Eli Lilly & company. How much will this progressive growth disrupt overall drug delivery and in other therapeutic areas?
There will be a series of brief but highly informative 'deep dive' presentations by leading experts on key drug delivery technologies ranging from large volume and wearable devices, nasal/pulmonary delivery, intradermal technologies, amongst others.
The day will include interactive roundtable sessions, and ample opportunity for Q&A discussions, including meeting the experts over networking lunch and coffee breaks.
We look forward to welcoming you!
Sincerely,
The Workshop Leader
Mathias Romacker, Kymanox
Scientific Program Planning Committee
- Mathias Romacker, Kymanox
- John Burke, Team Consulting
- Mehul Desai, Enable Injections
- Philippe Lauwers, Terumo
- Tom Sefrin, Roche
- Andrei Yosef, LTS Lohmann
- Falk Klar, PDA Europe
- Caroline Lynar, Manager Programs & Events, PDA Europe
Contact
Program Inquiries
Exhibition/Sponsorship Inquiries
Training Course Inquiries
Registration Customer Care
Standard Registration
Member Price
€ 1.080Non-Member
€ 1.080
ALL PRICES IN EURO (EUR), EXCLUDING VAT.
WAYS TO REGISTER: 1. Online Registration 2. [email protected]
PDA MEMBERS: Please remember to log in before registering If you come from a Governmental or Health Authority Institution or from an Academic Organization, please contact [email protected] before registering.
If you need to apply for a visa to enter the event country, PDA Europe must be informed of this fact at least 4 weeks before the start of the event.
Day 1
9:00 I Welcome Coffee |
---|
9:20 I Welcome and Introduction from the Workshop Leader |
---|
Mathias Romacker, Kymanox |
9:30 | Setting the Stage – The Rise and Potential Disruption Effects of GLP-1 Drugs for Drug Delivery |
---|
Anand Subramony, Eli Lilly & Company |
9:50 | Insights from the PDA Medical Devices and Connected Health Conference 2024 |
---|
Paul Upham, Roche/Genentech |
10:10 | An Introduction to Behaviour Design and Its Application to Medical Device Development |
---|
Geraint Davies, F. Hoffmann-La Roche |
10:30 | Overview of Established and Novel Drug Delivery Technologies |
---|
Mathias Romacker, Kymanox |
10:40 | Short Break |
10:50 | Interactive Session on Emerging Technologies |
---|
Join us for an engaging session focused on the latest technologies shaping our industry:
|
12:05 - 13:05 | Networking Lunch Break |
---|
13:05 | Reconvene to present and discuss the key findings from the roundtable discussions. Gain insights into the most compelling and relevant technologies as identified by our diverse group of participants |
---|
13:35 - 14:45 | Enabling technologies with hands-on experiences, Part I |
---|
13:35 | Topic: Intradermal, Presented by Speaker to be announced 13:45 | Topic: Nasal, Presented by Alain Regard, Nemera 13:55 | Topic: Pulmonary, Presented by Gonçalo Farias, Aptar 14:05 | Topic: Reusable Injection Devices, Presented by Gemma Wood, Phillips Medisize 14:15 | Topic: Large Volume Handheld Devices, Presented by Raphael Weiler, Ypsomed 14:25 - 14:45 | Hands-On Experience Part I |
14:45 - 15:05 | Networking Coffee Break |
---|
15:05 - 16:25 | Enabling technologies with hands-on experiences, Part II |
---|
15:05 | Topic: Pediatric Device Technolgies, Presented by Chris Hurlstone, Team Consulting 15:15 | Topic: Novel Drug Container Technologies Offering Opportunities for Better Sustainability and Form Factors, Presented by Paul Rutter, Apiject 15:25 | Topic: Large Volume Delivery, Presented by Aaron Swick, Enable Injections 15:35 | Topic: Ocular Technologies, Presented by Vincent Cazanave, Roche - remote presentation - 15:45 | Topic: Formulation, Presented by Wenyu Dong, Johnson & Johnson 15:55 | Topic: More than a theory - Successful delivery of biologics, mRNA and vaccines by Microarray Patch Technology, Presented by Markus Winterberg, LTS Lohmann 16:05 - 16:25 | Hands-On Experience Part II |
16:25 | Roundtable Discussion on Technologies Presented Before |
---|
16:55 | Interactive Questionnaire |
---|
17:00 | The Future of Drug Delivery – the Pharma Perspective - A Panel Discussion |
---|
Panelists:
|
18:00 | Farewell |
---|
Mathias Romacker, Kymanox |
18:10 I End of Workshop |
---|
Featured Presenters
-
Vincent Cazanave
Device Team Leader, Roche
Read BioVincent Cazanave
Roche
Principal Medical Device Engineer and more than 13 years of experience in drug delivery and combination product development in various leading roles. Belonging to the Device & Packaging development group at Roche, leading device teams in developing specific drug delivery solutions for molecules in the pipeline, and leading the global Roche/Genentech Ophthalmology Device Technology Center. -
Eric Chanie
Merck Group
Read BioEric Chanie
Merck Group
After an electronic engineering degree in France complemented by an MBA in Marketing, Eric Chanie joined a start-up company as Research & Development director involved in gas analysis for odor measurement. The company grew from 3 people to more than 100 with a successful IPO on the Paris stock exchange. In 2007, He then joined a medical device company developing miniaturized sensors for hemodialysis and neurosurgery (biosensing, intracranial pressure measurement) in which he leads the Research and Development team. He joined Merck Serono in 2010 as Medical Device innovation manager to strengthen product portfolio and contribute to the new generation of electronic devices. He was then appointed head of innovation in the newly created “Global Business Franchise Medical Devices” and got much more involved in business development and technology scouting in the space of digital health, AI & digital therapeutics. Eric joined a research organization in 2020 and co-founded a company called Epios, providing precision care for brain disorders enabled by implantable long-term brain sensing technology. In 2023, Eric joined back Merck as the head of device engineering and core team leader for connected pens.
-
Andrew Chapman
AstraZeneca
Read BioAndrew Chapman
AstraZeneca
Andrew Chapman, BEng, MBA, is a Senior Director at AstraZeneca in Biopharmaceutical Development, where he leads technology strategy and the evaluation, development and commercialisation of drug delivery technologies.
With over 21 years of experience developing breakthrough technologies for some of the world's largest pharmaceutical and medical technology companies, Andrew is known for his strategic thinking, clear communication, and adaptive leadership. Holding degrees in both engineering and business he is passionate about improving patients' lives through technological innovation.
Andrew's professional journey includes diverse roles ranging from project leadership to setting and executing organization-wide strategies, along with P&L responsibility for multimillion-dollar divisions. He has led strategic consulting projects in medical devices, connected devices, and digital health for industry leaders such as AbbVie, Roche, CSL Behring, Smith & Nephew, and Zimmer Biomet. Before joining AstraZeneca, Andrew served as Vice President at Sagentia and as Head of Digital Health at the UK government’s Digital Catapult.
-
Geraint Davies
F. Hoffmann-La Roche
Read BioGeraint Davies
F. Hoffmann-La Roche
Geraint is a Principal Human Factors Engineer and Behaviour Design Specialist at Roche. He has 20 years experience of Medical Device and Digital Health development, and predominantly works on connected Medical Devices, SaMD, Digital Biomarkers and Digital Therapeutics. With a background in Product Design and more recent education in the behaviour sciences, Geraint focuses on bridging the gap between the opportunities offered by digital technology and the realities of human behaviour.
-
Gonçalo Farias
Laboratory Manager for Nasal and Innovation Services, Aptar Pharma
Read BioGonçalo Farias
Aptar Pharma
Gonçalo Farias is currently working as a Laboratory Manager for Nasal and Innovation Services at Aptar Pharma (France). He holds an MSc in Pharmaceutical Sciences from the University of Lisbon, Portugal (2014), and a Ph.D. in Pharmacy & Pharmacology from the University of Bath, UK (2021). During his PhD, he focused on the investigation of formulation design and structure of orally inhaled and nasal drug products (OINDPs) and his work has been published in peer-reviewed journals. Gonçalo Farias has 10 years of experience on OINDPs, and his previous roles were linked to analytical development, but also formulation and device product development.
-
Serkan Oray, PhD
Vice President, Head of Devices, Artwork & Packaging, UCB Pharma
Read BioSerkan Oray, PhD
UCB Pharma
Serkan Oray leads an enterprise team within UCB covering development and industrialization of drug delivery systems, primary packaging, secondary packaging (including non-device products), and partnerships for digital and in vitro diagnostics. This team has grown organically over the last ten years, starting with the first subcutaneous drug delivery systems for UCB’s initial biologics portfolio and expanding to include additional modalities. Over this same period, Serkan’s team has been proud to be awarded multiple device design and packaging awards, including in the domain of sustainability. Prior to his work in device and packaging, Serkan’s career progressed through diverse functions at UCB, including medical affairs, commercial, and corporate strategy. He entered UCB in 2004 following an education in biomedical engineering and a PhD in Neuroscience from MIT.
-
Alain Regard
Technology Product Manager, Nemera
Read BioAlain Regard
Nemera
Alain Regard is a Technology Product Manager of Insight by Nemera based in Lyon, France.
Graduated in Polymer Engineering and Processing from Ecole Superieure de Plasturgie (ESP) in Oyonnax, France, Alain began his professional career as a design engineer in the automotive industry.
He joined the Nemera in 2010 as a Product Development Leader working on multiple projects related to pumps, sprays and pMDIs. Alain, today at the position of Technology Product Manager leads the innovation and early-stage concepts research in the fields of nasal drug delivery. Alain has a track record of 14 published patent families in the field of drug delivery. His main fields of expertise are design of nasal drug dispensing devices, atomization, spray generation and characterization as well as Ear Nose and Throat (ENT) anatomy and physiology.
-
Mathias Romacker
Kymanox
Read BioMathias Romacker
Kymanox
Mathias Romacker was most recently Senior Director, Device Strategy at Pfizer HQ in New York City. He joined Pfizer in March 2015. In this commercial role, he focused on the front end of device technology. He worked with multiple functions and sites across the organization to develop a device strategy for Pfizer pipeline and inline products.
Previously, for a duration of 9 years, Mathias worked in the device area for Amgen in Thousand Oaks, California. Before joining Amgen, he held multiple sales and marketing positions with Becton Dickinson and Gerresheimer in Germany, South Africa, and New Jersey. Mathias holds a Masters equivalent degree in economics from the University of Freiburg/Germany.
Mathias is on the PDA Board of Directors.
-
Paul Rutter
ApiJect
Read BioPaul Rutter
ApiJect
Paul Rutter is a British public health physician who has specialized and worked extensively in global health. His focus has been on understanding the reasons why healthcare delivery is not working at the front-line level and addressing them through major global health programs.
His extensive experience includes serving as: Chief Operations Officer of WHO’s global polio eradication program; Regional Health Adviser for UNICEF in South Asia; and, clinical adviser to England’s Chief Medical Officer. He is the author of the textbook Essential Public Health. He holds a Masters in Public Health from Harvard University, and an MBA from London Business School.
-
Anand Subramony, PhD
Eli Lilly & Company
Read BioAnand Subramony, PhD
Eli Lilly & Company
Anand Subramony is Vice President within the DDCS (Delivery, Device, and Connected Solutions) group at Eli Lilly and he provides leadership to early development of device combination products and novel drug delivery technologies. Prior to joining Lilly, Anand was Vice President within the Biologics Engineering and Targeted Delivery group, at AstraZeneca where he led various cross-functional teams and initiatives in the areas of nanomedicine -drug conjugates, and drug delivery of new modalities including implantable cell therapy devices. He also provided leadership to external innovation and CoSolve, an open innovation platform. Prior to that role Anand headed the Drug Delivery & Device Development at MedImmune/AZ and built an internal team that focused on combination product development, connected devices, digital biomarkers/sensors, as well as advanced novel delivery technologies including oral peptide delivery and other novel controlled release technologies. In other roles, Anand was Principal Fellow and Head of Novel Delivery Technologies at Novartis (NIBR, Cambridge, MA), head of the Materials Science group (E-TRANS) at Alza /J&J (Mountain View, CA), and Director of Materials Science & Drug delivery at Dr. Reddy’s Laboratories (Bridgewater, NJ). With his broad experience in pharma biotech, Anand brings innovation and scientific rigor coupled with execution excellence and sense of urgency to create patient centric products. He has established and managed high-performing teams in all his roles. Dr. Subramony holds an M.S. degree in Materials Science Engineering (IIT, Bombay) and a Ph.D. degree from Purdue University. With several refereed publications and patents, he is a sought-after Key Opinion Leader in the areas of drug delivery and product development.
-
Aaron Swick
Senior Staff Engineer for Research and Development, Enable Injections
Read BioAaron Swick
Enable Injections
As a Senior Staff Engineer for Research and Development at Enable Injections, Aaron Swick leads the connected healthcare program, driving collaborating with pharmaceutical partners to shape the evolution of enFuse technology. With over 15 years of experience in medical device and healthcare innovation, Mr. Swick leverages his extensive background in user and market research to steer product strategy and design. His diverse portfolio of work encompasses various healthcare technologies, including surgical instruments, diagnostics, capital equipment, consumer health and drug delivery products. He earned his MSE and BSE in Biomedical Engineering, and completed a post-graduate fellowship in medical innovation, all from the University of Michigan.
-
Paul Upham
Roche/Genentech
Read BioPaul Upham
Roche/Genentech
Paul is the Head of Smart Devices at Roche / Genentech. Paul has 20+ years of experience in medical device R&D, strategic marketing, product management, clinical research, and medical informatics.
Prior to Roche / Genentech, Paul was with Becton Dickinson(BD), as Worldwide Director of Strategic Marketing in their Pharmaceutical Systems business.
Paul was also the head of Product at WellDoc, Inc., where he led the product management activities for WellDoc’s portfolio of mobile health solutions. He was responsible for WellDoc’s landmark BlueStar™ product, a class II medical device and the world’s first reimbursed, prescription-only software for diabetes.
Paul’s prior experience includes 10 years in BD’s Diabetes Care business. Paul was responsible for the award-winning BD InterActiv® Diabetes Software, and was a member of the BD / Medtronic team that launched ParadigmLink®, the world’s first wireless blood glucose meter.
Paul holds four issued patents in medical software and drug delivery devices and has multiple patent applications. He is also an author of numerous peer-reviewed articles in medical informatics and diabetes. His education includes undergraduate studies in cognitive science and graduate work in health informatics and finance at the University of Minnesota and New York University.
-
Rafael Weiler
Ypsomed
Read BioRafael Weiler
Ypsomed
Rafael Weiler is a strategic leader in Digital Health, driving innovation and market growth through effective project and portfolio management. With a passion for cutting-edge technology and a knack for aligning initiatives with business goals, he fosters a culture of innovation and forward-thinking solutions.
-
Markus Winderberg, PhD
Head of Analytical Development, Microbiology, and Quality Control, LTS Lohmann Therapie Systeme
Read BioMarkus Winderberg, PhD
LTS Lohmann Therapie Systeme
Markus is Head of Analytical Development, Microbiology, and Quality Control for the MAP-Program at LTS Lohmann Therapie Systeme AG in Andernach. He studied biology at Philipps University in Marburg, Germany, and was awarded a PhD in Parasitology in 2009 for his work on the membrane physiology and biochemistry of the Malaria parasite. From 2009 to 2015 he expanded his track record in infectious disease research at The Australian National University in Canberra, Australia. In 2015, he accepted a position for the University of Oxford, leading the Clinical Pharmacology laboratories at the Mahidol-Oxford Tropical Medicine Research Unit in Bangkok, Thailand. Markus has extensive experience in bio-analytics and infectious disease research with more than 30 peer-reviewed publications and more than $3.5M of competitive research funding over the past years. He participated in more than 30 clinical trials (phase 1 - 4), bioavailability and bioequivalence studies. In 2019 he joined LTS as Head of Analytical Development for the MAP Program. He has been heading the Microbiology and Quality Control for the MAP Program since 2021.
-
Gemma Wood
Phillips Medisize
Read BioGemma Wood
Phillips Medisize
Gemma is currently Director, Platform Management at Phillips Medisize, focusing on their growing portfolio of injectable drug delivery platform devices. She has spent 25 years working in the drug delivery sector, with previous leadership roles across Innovation and Programme Management at Bespak/Recipharm, The Medical House, and Owen Mumford Ltd. Gemma has a Master's in Business Administration and is a CMI-certified Chartered Manager.
Presenters
-
Philippe Lauwers
Terumo Pharmaceutical Solutions
Philippe Lauwers
Terumo Pharmaceutical Solutions
Philippe Lauwers has been active in the medical device and pharmaceutical packaging sector for the last fifteen years with growing responsibilities in business development and technical roles. He is currently the Director of Technology Development at Terumo Pharmaceutical Solutions in Belgium. Philippe graduated in Biotechnology from the University in Ghent, Belgium, and worked as a scientific researcher at the Catholic University of Leuven. Upon obtaining an additional degree in Biomedical Engineering at the Catholic University of Leuven he moved from an academic to an industrial environment. Philippe is a volunteer at the PDA organization and also serves as an expert in ISO technical committees TC76 and TC84
-
Andrei Yosef, PhD
LTS
Andrei Yosef, PhD
LTS
Dr. Yosef ist the General Manager of LTS.
Leading expert in drug delivery device market and high end technologies. Dr Yosef applies his industry knowledge in both technology and business to steer forward Eitan Medical to develop and commercialize novel drug delivery device. Dr Yosef founded several startup companies in the field prior to him joining Q Core Medical. He served in several executive positions at Q Core for a decade, before taking the helm at pharmaceutical solutions of Eitan Medical including Sorrel’s wearable injectors products. Dr Yosef holds a PhD in Biomedical Engineering and an MA in Mechanical Engineering, both from the Technion – Israel Institute of technology.
Sponsorship and Exhibit Opportunities are available!
For more information about exhibit and sponsorship opportunities, please contact:
Christopher Härtig
Senior Manager Exhibition & Sponsorship
Email
Thank You to Our Sponsors
PLATINUM
Become a Sponsor
Interested in becoming a sponsor? Learn about opportunities and benefits.
Request InformationBecome an Exhibitor
Interested in becoming an exhibitor? Learn about opportunities and benefits.
Request InformationPLEASE READ PDA is not affiliated or contracted with any outside hotel contracting company. If someone other than PDA or the PDA chosen hotel contacts you suggesting that they represent any PDA event, they do not. It is PDA's recommendation that you book your hotel directly through the official PDA chosen hotel that is listed on our web site.
PDA recommends the reservation at the following hotel
Hilton Antwerp Old Town
Groenplaats 32
B2000 Antwerp
Belgium
PDA Europe has reserved a limited number of rooms by 01 April 2024.
Book your room at the PDA Group Rate via the above-mentioned reservation button.
How to Get Here
Travel and Exclusive Discount Information
Special Lufthansa Group Airlines Fares
The Lufthansa Group airlines bring people together – every day, all around the world.The global route network of Austrian Airlines, Lufthansa, SWISS, Brussels Airlines and Eurowings offers optimal connection and combination options, so you will benefit from quick and direct flights to the event.
You will reach the booking platform via this link https://www.lufthansa.com/de/en/meetings-and-events-delegates and with the event code DEAPILH. The reduced fares are automatically displayed.
Note: Please enable pop-ups permanently in your browser while booking, otherwise the window in the booking platform will not open.
Of course, you can also book through your IATA travel agency. The travel agency can request the ticketing instructions by sending an email to [email protected], stating the event code DEAPILH.
Book FlightSpecial Deutsche Bahn Train Fares
Get there relaxed – get there sustainable – travel CO2-free. Your Event Ticket at a fixed price throughout Germany. From any Deutsche Bahn station to our event, with the City-Ticket included.
Event Ticket one-way and specific train (subject to availability):
- 1st class 89,90€ (seat reservation incl.)
- 2nd class 55,90€
Event Ticket one-way and fully flexible:
- 1st class 112,90€ (seat reservation incl.)
- 2nd class 77,90€
Book online now and get the lowest price for your preferred route – guaranteed. For technical questions, please contact the service number +49 (0) 30 58 60 20 901. Create the perfect start for your sustainable event: Make active use of your journey to work or just relax and enjoy the high-speed travel experience – with 100% renewable power on regional and long-distance services.
Book Train